I’m not so concerned about timelines either. There are plenty of milestones coming up prior to FDA approval that should help increase value.
As a comparison look at EBR ($359m MC) & AVR ($331m MC) both have a significantly higher MC than EMV ($181m MC) yet they are still awaiting FDA approval. (Albeit both Class 3 devices).
EMvision Research Notes, page-2617
-
- There are more pages in this discussion • 87 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EMV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.05 |
Change
0.065(3.27%) |
Mkt cap ! $175.3M | |||
| Open | High | Low | Value | Volume |
| $2.00 | $2.05 | $2.00 | $35.10K | 17.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1206 | $2.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.05 | 5674 | 2 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| EMV (ASX) Chart |